Lipocine Operating Income vs Gross Profit Analysis
LPCN Stock | USD 5.44 0.12 2.26% |
Lipocine financial indicator trend analysis is infinitely more than just investigating Lipocine recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lipocine is a good investment. Please check the relationship between Lipocine Operating Income and its Gross Profit accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
Operating Income vs Gross Profit
Operating Income vs Gross Profit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lipocine Operating Income account and Gross Profit. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Lipocine's Operating Income and Gross Profit is 0.88. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Lipocine, assuming nothing else is changed. The correlation between historical values of Lipocine's Operating Income and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Lipocine are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Operating Income i.e., Lipocine's Operating Income and Gross Profit go up and down completely randomly.
Correlation Coefficient | 0.88 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Operating Income
Operating Income is the amount of profit realized from Lipocine operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lipocine is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Lipocine minus its cost of goods sold. It is profit before Lipocine operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most indicators from Lipocine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lipocine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.At this time, Lipocine's Selling General Administrative is very stable compared to the past year. As of the 18th of April 2024, Sales General And Administrative To Revenue is likely to grow to 46.82, while Tax Provision is likely to drop 411.40.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 5.3M | 4.1M | 15.1M | 15.8M | Cost Of Revenue | 7.7M | 8.6M | 28.7K | 27.2K |
Lipocine fundamental ratios Correlations
Click cells to compare fundamentals
Lipocine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lipocine fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 29.7M | |
Other Current Liab | 449.3K | 1.7M | 1M | 1.1M | 1.2M | 1.5M | |
Total Current Liabilities | 5.0M | 6.6M | 5.6M | 1.7M | 2.6M | 3.4M | |
Total Stockholder Equity | 6.3M | 15.3M | 45.6M | 35.6M | 20.4M | 24.6M | |
Net Debt | (2.6M) | (13.6M) | (639.7K) | (3.1M) | (4.8M) | (5.0M) | |
Retained Earnings | (151.1M) | (172.0M) | (172.7M) | (183.4M) | (199.8M) | (189.8M) | |
Accounts Payable | 1.2M | 1.6M | 1.3M | 600.4K | 1.4M | 798.8K | |
Cash | 9.7M | 19.2M | 3.0M | 3.1M | 4.8M | 9.2M | |
Cash And Short Term Investments | 14.1M | 19.7M | 44.6M | 32.5M | 22.0M | 26.6M | |
Common Stock Total Equity | 2.2K | 3.8K | 7.0K | 8.8K | 10.2K | 10.7K | |
Common Stock Shares Outstanding | 1.5M | 3.3M | 5.1M | 5.2M | 5.3M | 5.5M | |
Liabilities And Stockholders Equity | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 29.7M | |
Other Current Assets | 545.9K | 661.3K | 1.5M | 945.3K | 773.4K | 1.0M | |
Other Stockholder Equity | 157.4M | 187.4M | 218.2M | 219.1M | 220.1M | 147.6M | |
Total Liab | 13.4M | 10.0M | 6.9M | 1.9M | 2.6M | 5.1M | |
Total Current Assets | 19.6M | 25.3M | 46.4M | 34.1M | 22.9M | 28.8M | |
Accumulated Other Comprehensive Income | (963.0) | (38.0) | (18.0K) | (20.3K) | 7.3K | 7.6K | |
Common Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 9.3K | |
Property Plant Equipment | 19.0K | 3.6K | 7.2K | 131.6K | 118.4K | 124.4K | |
Net Tangible Assets | 6.3M | 15.3M | 45.6M | 35.6M | 41.0M | 27.0M | |
Retained Earnings Total Equity | (138.1M) | (151.1M) | (172.0M) | (172.7M) | (155.4M) | (163.2M) | |
Short Term Investments | 4.3M | 450.0K | 41.7M | 29.4M | 17.3M | 15.1M | |
Capital Surpluse | 147.5M | 157.4M | 187.4M | 218.3M | 251.0M | 143.4M | |
Property Plant And Equipment Net | 3.6K | 0.0 | 7.2K | 131.6K | 116.1K | 63.4K | |
Non Current Assets Total | 27.3K | 23.8K | 6.1M | 3.4M | 139.8K | 132.9K | |
Property Plant And Equipment Gross | 3.6K | 1.1M | 1.2M | 1.3M | 1.3M | 1.4M | |
Net Receivables | 16.5K | 391.0 | 247.3K | 659.9K | 52.3K | 49.6K | |
Net Invested Capital | 13.4M | 20.9M | 47.9M | 35.6M | 20.4M | 27.8M | |
Net Working Capital | 14.7M | 18.7M | 40.8M | 32.5M | 20.2M | 25.5M | |
Short Long Term Debt Total | 7.1M | 5.6M | 2.3M | 17.2K | 15.4K | 14.7K | |
Capital Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 7.2K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Lipocine Stock analysis
When running Lipocine's price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share (0.54) | Quarterly Revenue Growth (1.00) | Return On Assets (0.37) | Return On Equity (0.58) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.